TransMedics: 2023 Earnings & Future Insights
Medical technology company TransMedics Group, Inc. is set to release its Q4 and full year 2023 financial results, highlighting its ...
- Latest
- Trending
Medical technology company TransMedics Group, Inc. is set to release its Q4 and full year 2023 financial results, highlighting its ...
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.